Haemonetics Corp (NYSE: HAE)’s stock price has gone rise by 1.35 in comparison to its previous close of 61.31, however, the company has experienced a -1.35% decrease in its stock price over the last five trading days. prnewswire.com reported 2025-02-13 that – ANDEMBRY®, the first and only once-monthly treatment targeting factor XIIa to prevent attacks in HAE patients, inhibits plasma protein factor XIIa, which initiates the cascade of events leading to angioedema at various sites of the body- ANDEMBRY reinforces CSL’s decades-long commitment to delivering innovative treatment modalities to the HAE community and comes with a convenient patient-centric pre-filled pen (auto-injector) enabling subcutaneous self-injection- Supported by the Phase 3 VANGUARD trial, this marks the third regulatory approval for ANDEMBRY, which was also recently approved by Australia’s Therapeutic Goods Administration (TGA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) in January MARBURG, Germany, Feb. 13, 2025 /PRNewswire/ — Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced that the European Commission (EC) has approved ANDEMBRY® (garadacimab), the first and only once-monthly treatment targeting factor XIIa to prevent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older. ANDEMBRY inhibits plasma protein factor XIIa, which initiates the cascade of events leading to angioedema at various sites of the body.
Is It Worth Investing in Haemonetics Corp (NYSE: HAE) Right Now?
Haemonetics Corp (NYSE: HAE) has a higher price-to-earnings ratio of 24.45x compared to its average ratio. HAE has 36-month beta value of 0.43. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 5 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for HAE is 49.44M, and currently, short sellers hold a 10.60% ratio of that float. The average trading volume of HAE on February 13, 2025 was 752.51K shares.
HAE’s Market Performance
The stock of Haemonetics Corp (HAE) has seen a -1.35% decrease in the past week, with a -22.29% drop in the past month, and a -32.01% fall in the past quarter. The volatility ratio for the week is 5.63%, and the volatility levels for the past 30 days are at 4.77% for HAE. The simple moving average for the past 20 days is -8.65% for HAE’s stock, with a -23.35% simple moving average for the past 200 days.
Analysts’ Opinion of HAE
Many brokerage firms have already submitted their reports for HAE stocks, with BofA Securities repeating the rating for HAE by listing it as a “Underperform.” The predicted price for HAE in the upcoming period, according to BofA Securities is $68 based on the research report published on February 07, 2025 of the current year 2025.
JP Morgan, on the other hand, stated in their research note that they expect to see HAE reach a price target of $116. The rating they have provided for HAE stocks is “Overweight” according to the report published on December 06th, 2024.
Raymond James gave a rating of “Strong Buy” to HAE, setting the target price at $120 in the report published on November 08th of the previous year.
HAE Trading at -17.31% from the 50-Day Moving Average
After a stumble in the market that brought HAE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.57% of loss for the given period.
Volatility was left at 4.77%, however, over the last 30 days, the volatility rate increased by 5.63%, as shares sank -17.31% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -29.05% lower at present.
During the last 5 trading sessions, HAE fell by -1.48%, which changed the moving average for the period of 200-days by -31.79% in comparison to the 20-day moving average, which settled at $68.02. In addition, Haemonetics Corp saw -20.41% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HAE starting from Lingamneni Anila, who proposed sale 6,238 shares at the price of $90.68 back on Nov 11 ’24. After this action, Lingamneni Anila now owns shares of Haemonetics Corp, valued at $565,692 using the latest closing price.
Strong Stewart W, the President, Global Hospital of Haemonetics Corp, sale 4,312 shares at $91.15 during a trade that took place back on Jul 26 ’24, which means that Strong Stewart W is holding 18,196 shares at $393,039 based on the most recent closing price.
Stock Fundamentals for HAE
Current profitability levels for the company are sitting at:
- 0.15 for the present operating margin
- 0.52 for the gross margin
The net margin for Haemonetics Corp stands at 0.09. The total capital return value is set at 0.09. Equity return is now at value 14.06, with 5.50 for asset returns.
Based on Haemonetics Corp (HAE), the company’s capital structure generated 0.57 points at debt to capital in total, while cash flow to debt ratio is standing at 0.11. The debt to equity ratio resting at 1.35. The interest coverage ratio of the stock is 6.97.
Currently, EBITDA for the company is 265.58 million with net debt to EBITDA at 3.44. When we switch over and look at the enterprise to sales, we see a ratio of 2.94. The receivables turnover for the company is 6.48for trailing twelve months and the total asset turnover is 0.54. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.97.
Conclusion
To put it simply, Haemonetics Corp (HAE) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
